Skip to main content
OpenTrials
Completed

NCT Number: NCT01744561

Effects of a Partially Supervised Conditioning Program in CF

Physical activity and exercise have become an accepted and valued component of Cystic Fibrosis care. Regular physical activity and exercise can slow the rate of decline of pulmonary function, improve physical fitness, and enhance quality of life. However, motivating people to be more active is challenging. Supervised exercise programs are expensive and labor intensive, and adherence falls off significantly once supervision ends. Unsupervised or partially supervised programs are less costly and more flexible, but compliance can be more problematic. The primary objective of this study is to evaluate the effects of a 12-months partially supervised exercise intervention along with regular motivation on forced expiratory volume in 1 second (FEV1) in a large international group of cystic fibrosis patients. Secondary endpoints include patient reported quality of life, as well as levels of anxiety and depression, and control of blood sugar. A total of 292 patients with cystic fibrosis 12 years and older with a FEV1 ≥35% predicted will be recruited. Following baseline assessments (2 visits) patients will be randomized into an intervention and a control group. Thereafter, they will be seen every 3 months for assessments in their centre for one year (4 follow-up visits). Along with individual counseling to increase vigorous physical activity by at least 3 hours per week on each clinic visit, the intervention group will document daily exercise and inactivity time and will receive a step counter and they will record their progress with a web-based program. They will also receive monthly phone calls from the study staff. After 6 months, they will continue with the step counter and web-based program for a further 6 months. The control group will receive access to this intervention after 12 months of standardized care. Should this relatively simple program prove successful, this will be made available on a wider scale internationally.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mukoviszidose-Ambulanz, Universitätsklinik für Kinder- und Jugendheilkunde,, Graz, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of Cystic Fibrosis
  • Age ≥12 years
  • Forced expiratory volume in 1 second (FEV1) ≥ 35% predicted
  • Access to the internet

Exclusion criteria

  • Participation in another clinical trial up to 4 weeks prior to the first baseline visit
  • Pregnancy/Breastfeeding
  • Inability to exercise
  • More than 4 hours of reported strenuous physical activities per week currently or up to 3 months prior to baseline measurements and not already planned within the coming 6 months.
  • Unstable condition precluding exercise (major hemoptysis or pneumothorax within the last 3 months, acute exacerbation and iv-antibiotics during the last 4 weeks, planned surgery, listed for lung transplantation, major musculoskeletal injuries such as fractures or sprains during the last 2 months, others according to the impression of the doctor)
  • Cardiac arrhythmias with exercise
  • Requiring additional oxygen with exercise
  • Recent diagnosis of diabetes 3 months prior to screening or at screening
  • Recent changes in medication 1 month or less prior to screening (systemic steroids, ibuprofen, inhaled antibiotics, mannitol, DNAse, hypertonic saline)
  • At least one G551D mutation and not on ivacaftor (VX770) yet but planned start or planned stop of ivacaftor during the trial
  • Colonization with Burkholderia cenocepacia

Treatment and study plan

Exercise Intervention

Behavioral

Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.

Primary outcomes

  1. Change in forced expiratory volume in 1 second (FEV1; in % predicted using the average of two baseline measurements) from baseline to 6 months in the intervention group compared to controls.

    Time frame: baseline and 6 months

Secondary outcomes

  1. Change in peak oxygen uptake (%predicted)

    Time frame: baseline to 6 months and baseline to 12 months

  2. Change in maximal aerobic power (%predicted)

    Time frame: baseline to 6 months and baseline to 12 months

  3. Change in measured steps per day

    Time frame: baseline to 6 months and baseline to 12 months

  4. Change in exercise steps per day

    Time frame: baseline to 6 months and baseline to 12 months

  5. Change in reported physical activity

    Time frame: baseline to 6 months and baseline to 12 months

  6. Change in forced expiratory volume in 1 second (FEV1; %predicted)

    Time frame: baseline to 6 months and baseline to 12 months

  7. Change in forced vital capacity (FVC; % predicted)

    Time frame: baseline to 6 months and baseline to 12 months

  8. Change in residual volume in percent of total lung capacity (RV/TLC; %)

    Time frame: baseline to 6 months and baseline to 12 months

  9. Time to first exacerbation

    Time frame: baseline to 6 months and baseline to 12 months

  10. Number of upper respiratory tract infections

    Time frame: baseline to 6 months and baseline to 12 months

    from diary

  11. Days on additional oral / intravenous antibiotics

    Time frame: baseline to 6 months and baseline to 12 months

    from questionnaire

  12. Change in body mass index (kg/m2)

    Time frame: baseline to 6 months and baseline to 12 months

  13. Change in muscle mass (kg)

    Time frame: baseline to 6 months and baseline to 12 months

    estimated from skinfold thickness

  14. Change in percent body fat

    Time frame: baseline to 6 months and baseline to 12 months

    estimated from skinfold thickness

  15. Change in Quality of Life scales

    Time frame: baseline to 6 months and baseline to 12 months

    from the revised Cystic Fibrosis health-related quality of life Questionnaire (CFQ-R questionnaire)

  16. Change in depression, anxiety and stress scores

    Time frame: baseline to 6 months and baseline to 12 months

    from Depression Anxiety Stress Scales

  17. Change in plasma glucose concentrations 1 and 2 hours after a standardized glucose load

    Time frame: baseline to 9 months

    standardized oral glucose tolerance test only patients without diabetes mellitus

  18. Adverse events possibly or likely related to exercise

    Time frame: baseline to 6 months and baseline to 12 months

    causality as judged by investigator

  19. Severe adverse events

    Time frame: baseline to 6 months and baseline to 12 months

  20. Serious adverse events

    Time frame: baseline to 6 months and baseline to 12 months

Other outcomes

  1. Compliance with the exercise goal

    Time frame: baseline to 6 months and baseline to 12 months

    based on questionnaire and diary

  2. Change in lung clearance index

    Time frame: baseline to 6 months and baseline to 12 months

    based on nitrogen multiple breath washout, in selected centres only

  3. Change in time spent in moderate-and-vigorous physical activity

    Time frame: baseline to 6 months and baseline to 12 months

    based on accelerometry, in selected centres only

  4. Change in bone mineral density and body composition

    Time frame: baseline to 6 months and baseline to 12 months

    based on dual energy x-ray absorptiometry, in selected centres only

  5. Change in mucociliary clearance with exercise

    Time frame: baseline to 6 months

    based on nuclear medicine scans, US centres only

Sponsors and collaborators

Lead sponsor

Wuerzburg University Hospital

Other

Registry information

Official study title

Effects of a Partially Supervised Conditioning Program in CF: an International Multi-centre, Randomized Controlled Trial

Acronym: ACTIVATE-CF

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Dec 6, 2012
Registry last updated
Oct 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.